120 related articles for article (PubMed ID: 24737876)
21. Variation in treatment and outcome in patients with non-small cell lung cancer by region, hospital type and volume in the Netherlands.
Wouters MW; Siesling S; Jansen-Landheer ML; Elferink MA; Belderbos J; Coebergh JW; Schramel FM
Eur J Surg Oncol; 2010 Sep; 36 Suppl 1():S83-92. PubMed ID: 20598845
[TBL] [Abstract][Full Text] [Related]
22. What is the extent of the advantage of video-assisted thoracoscopic surgical resection over thoracotomy in terms of delivery of adjuvant chemotherapy following non-small-cell lung cancer resection?
Teh E; Abah U; Church D; Saka W; Talbot D; Belcher E; Black E
Interact Cardiovasc Thorac Surg; 2014 Oct; 19(4):656-60. PubMed ID: 25015538
[TBL] [Abstract][Full Text] [Related]
23. Lung cancer treatment in New Zealand: physician's attitudes.
Christmas T; Findlay M
N Z Med J; 2004 Jun; 117(1196):U931. PubMed ID: 15280935
[TBL] [Abstract][Full Text] [Related]
24. [Quality assurance].
Flentje M; Hoffmann H; Huber RM
Onkologie; 2012; 35 Suppl 3():14-6. PubMed ID: 22678020
[No Abstract] [Full Text] [Related]
25. Nonsmall cell lung cancer presenting with synchronous solitary brain metastasis.
Hu C; Chang EL; Hassenbusch SJ; Allen PK; Woo SY; Mahajan A; Komaki R; Liao Z
Cancer; 2006 May; 106(9):1998-2004. PubMed ID: 16572401
[TBL] [Abstract][Full Text] [Related]
26. High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation.
Mamon HJ; Yeap BY; Jänne PA; Reblando J; Shrager S; Jaklitsch MT; Mentzer S; Lukanich JM; Sugarbaker DJ; Baldini EH; Berman S; Skarin A; Bueno R
J Clin Oncol; 2005 Mar; 23(7):1530-7. PubMed ID: 15735128
[TBL] [Abstract][Full Text] [Related]
27. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
[TBL] [Abstract][Full Text] [Related]
28. External audit of clinical practice and medical decision making in a new Asian oncology center: results and implications for both developing and developed nations.
Shakespeare TP; Back MF; Lu JJ; Lee KM; Mukherjee RK
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):941-7. PubMed ID: 16297568
[TBL] [Abstract][Full Text] [Related]
29. Stage III non-small-cell lung cancer: Establishing a benchmark for the proportion of patients suitable for radical treatment.
Al-Shamsi HO; Al Farsi A; Ellis PM
Clin Lung Cancer; 2014 Jul; 15(4):274-80. PubMed ID: 24685356
[TBL] [Abstract][Full Text] [Related]
30. Non-small cell lung cancer in young adults: presentation and survival in the English National Lung Cancer Audit.
Rich AL; Khakwani A; Free CM; Tata LJ; Stanley RA; Peake MD; Hubbard RB; Baldwin DR
QJM; 2015 Nov; 108(11):891-7. PubMed ID: 25725079
[TBL] [Abstract][Full Text] [Related]
31. Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature?
Langer CJ; Moughan J; Movsas B; Komaki R; Ettinger D; Owen J; Wilson JF
Lung Cancer; 2005 Apr; 48(1):93-102. PubMed ID: 15777975
[TBL] [Abstract][Full Text] [Related]
32. Improving the quality of lung cancer care in Ontario: the lung cancer disease pathway initiative.
Evans WK; Ung YC; Assouad N; Chyjek A; Sawka C
J Thorac Oncol; 2013 Jul; 8(7):876-82. PubMed ID: 23575416
[TBL] [Abstract][Full Text] [Related]
33. Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis.
Kuiper JL; Hendriks LE; van der Wekken AJ; de Langen AJ; Bahce I; Thunnissen E; Heideman DA; Berk Y; Buijs EJ; Speel EJ; Krouwels FH; Smit HJ; Groen HJ; Dingemans AM; Smit EF
Lung Cancer; 2015 Sep; 89(3):255-61. PubMed ID: 26117231
[TBL] [Abstract][Full Text] [Related]
34. Health related quality of life in locally advanced NSCLC treated with high dose radiotherapy and concurrent chemotherapy or cetuximab--pooled results from two prospective clinical trials.
Hallqvist A; Bergman B; Nyman J
Radiother Oncol; 2012 Jul; 104(1):39-44. PubMed ID: 22727262
[TBL] [Abstract][Full Text] [Related]
35. Waiting times in early-stage non-small cell lung cancer (NSCLC).
Saint-Jacques N; Rayson D; Al-Fayea T; Virik K; Morzycki W; Younis T
J Thorac Oncol; 2008 Aug; 3(8):865-70. PubMed ID: 18670304
[TBL] [Abstract][Full Text] [Related]
36. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer.
Butts C; Murray N; Maksymiuk A; Goss G; Marshall E; Soulières D; Cormier Y; Ellis P; Price A; Sawhney R; Davis M; Mansi J; Smith C; Vergidis D; Ellis P; MacNeil M; Palmer M
J Clin Oncol; 2005 Sep; 23(27):6674-81. PubMed ID: 16170175
[TBL] [Abstract][Full Text] [Related]
37. Regional differences in treatment and outcome in non-small cell lung cancer: a population-based study (Sweden).
Myrdal G; Lamberg K; Lambe M; Ståhle E; Wagenius G; Holmberg L
Lung Cancer; 2009 Jan; 63(1):16-22. PubMed ID: 18571760
[TBL] [Abstract][Full Text] [Related]
38. Setting the bar: compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center.
Liang MI; ElNaggar AC; Nekkanti S; O'Malley DM; Hade EM; Copeland LJ; Fowler JM; Salani R; Backes FJ; Cohn DE
Gynecol Oncol; 2015 Sep; 138(3):689-93. PubMed ID: 26216728
[TBL] [Abstract][Full Text] [Related]
39. Prognostic factors in stage III non-small-cell lung cancer.
Ademuyiwa FO; Johnson CS; White AS; Breen TE; Harvey J; Neubauer M; Hanna NH
Clin Lung Cancer; 2007 Sep; 8(8):478-82. PubMed ID: 17922971
[TBL] [Abstract][Full Text] [Related]
40. Non-small cell lung cancer in octogenarians: treatment practices and preferences.
Oxnard GR; Fidias P; Muzikansky A; Sequist LV
J Thorac Oncol; 2007 Nov; 2(11):1029-35. PubMed ID: 17975495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
